American Renal Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of American Renal Associates Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARA

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of American Renal Associates Holdings, Inc. (NYSE: ARA) to Innovative Renal Care, LLC (“IRC”), an affiliate of Nautic Partners, LLC, for $11.50 per share in cash is fair to American Renal shareholders. On behalf of American Renal shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

If you are an American Renal shareholder and would like to discuss your legal rights and options, visit American Renal Merger or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether American Renal and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for American Renal shareholders; (2) determine whether IRC is underpaying for American Renal; and (3) disclose all material information necessary for American Renal shareholders to adequately assess and value the proposed transaction.

If you are an American Renal shareholder and would like to discuss your legal rights and options, visit https://halpersadeh.com/actions/american-renal-associates-holdings-inc-ara-stock-merger-nautic/ or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.